Summary & Overview
HCPCS M0247: Intravenous Infusion of Sotrovimab, Includes Monitoring
HCPCS Level II code M0247 denotes an intravenous infusion of sotrovimab, inclusive of the infusion procedure and required post-administration monitoring. As a code for a monoclonal antibody infusion, it is nationally relevant for payers, infusion providers, and health systems managing outpatient biologic therapies. Coverage and payment policy for such therapies affect access, site-of-service decisions, and operational workflows in ambulatory infusion centers and hospital outpatient departments.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents clinically, common billing considerations, and expected places of service. The publication summarizes benchmarking and policy context where available, highlights operational implications for infusion providers, and outlines areas where payers commonly apply coverage rules or utilization management. Data not available in the input is noted where applicable. This briefing is intended to inform administrators, billing staff, and policy teams about the code’s clinical meaning, typical use cases, and payer landscape at a national level.
Billing Code Overview
HCPCS Level II code M0247 describes an intravenous infusion of sotrovimab, including the infusion and post-administration monitoring. The service type is a monoclonal antibody infusion therapy for passive immunization. The typical site of service is an outpatient infusion setting such as an ambulatory infusion center, hospital outpatient department, physician office infusion suite, or other outpatient clinic configured for IV biologic administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with mild-to-moderate COVID-19 infection at high risk for progression to severe disease (for example, age ≥65, immunocompromised status, or with comorbidities such as chronic lung disease, diabetes, or chronic kidney disease). The patient presents to an outpatient infusion center, emergency department infusion suite, or hospital observation unit within the eligible treatment window after symptom onset. After evaluation by an authorized clinician (often an infectious disease physician, emergency medicine physician, or advanced practice provider), informed consent is obtained and baseline vital signs are recorded. Intravenous access is established, and M0247 is administered according to the manufacturer’s dosing and infusion rate guidelines. Continuous monitoring is performed during infusion and for a specified post-administration observation period to detect infusion-related reactions or hypersensitivity. Documentation includes indication, informed consent, lot number, dose, start and stop times, pre- and post-vital signs, adverse reaction assessment, and disposition (discharged home, observed, or admitted). Nursing staff and a supervising physician or advanced practice provider are typically present; resuscitation equipment and medications for anaphylaxis are available on site.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |